- Home
- IONS
as of 03-10-2026 3:53pm EST
$75.65
+$0.29
+0.38%
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 13.5B | IPO Year: | 1996 |
| Target Price: | $85.91 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.38 | EPS Growth: | 21.71 |
| 52 Week Low/High: | $23.95 - $86.74 | Next Earning Date: | 05-25-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -9.65% | Revenue Growth (next year): | 66.43% |
| P/E Ratio: | -31.14 | Index: | N/A |
| Free Cash Flow: | -320027000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
LOSCALZO JOSEPH
Sell
Director
IONS Mar 4, 2026
Avg Cost/Share
$80.00
Shares
200
Total Value
$16,000.00
Owned After
36,330
SEC Form 4
Baroldi Joseph
Sell
EVP, Chief Business Officer
IONS Mar 4, 2026
Avg Cost/Share
$80.00
Shares
439
Total Value
$35,120.00
Owned After
4,347
LOSCALZO JOSEPH
Sell
Director
IONS Mar 3, 2026
Avg Cost/Share
$80.33
Shares
832
Total Value
$66,832.81
Owned After
36,330
SEC Form 4
Baroldi Joseph
Sell
EVP, Chief Business Officer
IONS Mar 3, 2026
Avg Cost/Share
$80.26
Shares
6,220
Total Value
$495,866.62
Owned After
4,347
BENNETT C FRANK
Sell
EVP, Chief Scientific Officer
IONS Mar 3, 2026
Avg Cost/Share
$79.91
Shares
85,089
Total Value
$6,741,669.17
Owned After
94,043
KLEIN JOSEPH III
Sell
Director
IONS Mar 3, 2026
Avg Cost/Share
$80.00
Shares
21,332
Total Value
$1,696,181.37
Owned After
12,026
Diaz Allene M.
Sell
Director
IONS Mar 3, 2026
Avg Cost/Share
$79.93
Shares
54,878
Total Value
$4,354,428.21
Owned After
19,424
Devers Shannon L.
Sell
EVP, Chief Human Resources Ofc
IONS Mar 3, 2026
Avg Cost/Share
$79.98
Shares
20,106
Total Value
$1,596,432.82
Owned After
28,326
Swayze Eric
Sell
EVP Research
IONS Feb 13, 2026
Avg Cost/Share
$81.81
Shares
15,642
Total Value
$1,278,913.96
Owned After
38,312
PARSHALL B LYNNE
Sell
Director
IONS Feb 11, 2026
Avg Cost/Share
$82.72
Shares
5,000
Total Value
$413,588.50
Owned After
56,344
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| LOSCALZO JOSEPH | IONS | Director | Mar 4, 2026 | Sell | $80.00 | 200 | $16,000.00 | 36,330 | |
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Mar 4, 2026 | Sell | $80.00 | 439 | $35,120.00 | 4,347 | |
| LOSCALZO JOSEPH | IONS | Director | Mar 3, 2026 | Sell | $80.33 | 832 | $66,832.81 | 36,330 | |
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Mar 3, 2026 | Sell | $80.26 | 6,220 | $495,866.62 | 4,347 | |
| BENNETT C FRANK | IONS | EVP, Chief Scientific Officer | Mar 3, 2026 | Sell | $79.91 | 85,089 | $6,741,669.17 | 94,043 | |
| KLEIN JOSEPH III | IONS | Director | Mar 3, 2026 | Sell | $80.00 | 21,332 | $1,696,181.37 | 12,026 | |
| Diaz Allene M. | IONS | Director | Mar 3, 2026 | Sell | $79.93 | 54,878 | $4,354,428.21 | 19,424 | |
| Devers Shannon L. | IONS | EVP, Chief Human Resources Ofc | Mar 3, 2026 | Sell | $79.98 | 20,106 | $1,596,432.82 | 28,326 | |
| Swayze Eric | IONS | EVP Research | Feb 13, 2026 | Sell | $81.81 | 15,642 | $1,278,913.96 | 38,312 | |
| PARSHALL B LYNNE | IONS | Director | Feb 11, 2026 | Sell | $82.72 | 5,000 | $413,588.50 | 56,344 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 25, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 25, 2026 · 100% conf.
AI Prediction SELL
1D
-0.83%
$80.26
Act: -0.41%
5D
-4.02%
$77.67
Act: -1.25%
20D
-3.98%
$77.71
Price: $80.93 Prob +5D: 0% AUC: 1.000
0001140361-26-006718
false000087401500008740152026-02-252026-02-25
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 25, 2026
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-19125
33-0336973
(Commission File No.)
(IRS Employer Identification No.)
2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol
Name of each exchange on which registered
Common Stock, $.001 Par Value
“IONS”
The Nasdaq Stock Market, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On February 25, 2026, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2025. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release is furnished with this report as an exhibit pursuant to “Item 2.02. Results of Operations and Financial Condition” of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated February 25, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Ionis Pharmaceuticals, Inc.
Dated: February 25, 2026
By:
/s/ Patrick R. O’Neil
Patrick R. O’Neil
Executive Vice President, Chief Legal Officer and General Counsel
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
-0.83%
$80.26
Act: -0.41%
5D
-4.02%
$77.67
Act: -1.25%
20D
-3.98%
$77.71
Price: $80.93 Prob +5D: 0% AUC: 1.000
0001140361-26-000893
false000087401500008740152026-01-122026-01-12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 12, 2026
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-19125
33-0336973
(Commission File No.)
(IRS Employer Identification No.)
2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol
Name of each exchange on which registered
Common Stock, $.001 Par Value
“IONS”
The Nasdaq Stock Market, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On January 12, 2026, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing TRYNGOLZA® 2025 preliminary U.S. net product sales of $105 million. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results in February 2026.
The information in this Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated January 12, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Ionis Pharmaceuticals, Inc.
Dated: January 12, 2026
By:
/s/ Patrick R. O’Neil
Patrick R. O’Neil
Executive Vice President, Chief Legal Officer and General Counsel
2025 Q3 Q3 2025 Earnings
8-K Oct 29, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 29, 2025
0001140361-25-039650
false000087401500008740152025-10-292025-10-29
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 29, 2025
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-19125
33-0336973
(Commission File No.)
(IRS Employer Identification No.)
2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol
Name of each exchange on which registered
Common Stock, $.001 Par Value
“IONS”
The Nasdaq Stock Market, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On October 29, 2025, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release is furnished with this report as an exhibit pursuant to “Item 2.02. Results of Operations and Financial Condition” of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated October 29, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Ionis Pharmaceuticals, Inc.
Dated: October 29, 2025
By:
/s/ Patrick R. O’Neil
Patrick R. O’Neil
Executive Vice President, Chief Legal Officer and General Counsel
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
MT Newswires
Ionis Pharmaceuticals Insider Sold Shares Worth $1,696,181, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
MT Newswires
Ionis Pharmaceuticals Insider Sold Shares Worth $4,354,428, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
Compare IONS vs Leading Stocks
See how IONS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.